Registered title, quoted from ClinicalTrials.gov
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07535762, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
65 years to Not stated; sex: all
Registered eligibility fields
Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) who have not previously received treatment
Inclusion criterion 5
Previous immunotherapy or chemotherapy for PTCL, excluding those who used corticosteroids (≤8 days) prior to enrollment
Exclusion criterion 3
ECOG performance status score ≤ 2
Inclusion criterion 3
Absolute neutrophil count (ANC) ≥ 1,500/μL
Inclusion criterion 11
Platelet count ≥ 100,000/μL
Inclusion criterion 12
Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the institution (except for patients with Gilbert's syndrome)
Inclusion criterion 13
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; if liver involvement is known, then ≤ 5.0 × ULN
Inclusion criterion 14
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance > 50 mL/min calculated by the Cockcroft-Gault formula
Inclusion criterion 15
Known or detected positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B, or hepatitis C.
Exclusion criterion 15
Patients diagnosed with malignancy within the past two years. However, the following are excluded: non-melanoma skin cancer, melanoma in situ, localized prostate cancer (current PSA <0.1 ng/mL), treated thyroid cancer; or cervical carcinoma in situ or breast ductal/lobular carcinoma in situ within the past two years, provided there is currently no evidence of active disease.
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07535762, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Understand and voluntarily sign the informed consent form
- Age ≥ 65 years at enrollment
- ECOG performance status score ≤ 2
- Able to comply with the research visit plan and other protocol requirements
- Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) who have not previously received treatment
The following subtypes as defined by the World Health Organization (WHO) classification (2022) are eligible, with Ann Arbor stage I-IV, and pathological immunohistochemical CD30 negative:
- Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)
- Nodal T-follicular helper cell lymphoma (TFH)
- Anaplastic large cell lymphoma, ALK-negative (ALCL)
- Life expectancy ≥ 3 months
- Hematological, renal, and hepatic function all meet the requirements:
- Absolute neutrophil count (ANC) ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the institution (except for patients with Gilbert's syndrome)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; if liver involvement is known, then ≤ 5.0 × ULN
- Serum creatinine ≤ 1.5 × ULN, or creatinine clearance > 50 mL/min calculated by the Cockcroft-Gault formula
Exclusion Criteria:
- Mental illness, disability, or social circumstances that may affect participant safety, ability to provide informed consent, or poor adherence
- Other types of lymphoma
- Previous immunotherapy or chemotherapy for PTCL, excluding those who used corticosteroids (≤8 days) prior to enrollment
- Previous radiotherapy for PTCL, excluding those confined to a single lymph node region
- Pathological immunohistochemistry showing CD30 positivity and/or ALK positivity
- Patients planning to receive autologous or allogeneic transplantation as first-line consolidation therapy
- Confirmed central nervous system/meningeal involvement
- Significant uncontrolled comorbidities or infections, specifically:
- Uncontrolled infection requiring intravenous antibiotics
- Clinically significant heart disease (NYHA Class III or IV), unstable angina
- History of angioplasty, stent implantation, or myocardial infarction within the past 6 months
- Uncontrolled hypertension (systolic blood pressure >160 mmHg) despite using two antihypertensive medications. (or diastolic blood pressure >100 mmHg, measured twice consecutively, one week apart)
- Clinically significant cardiac arrhythmias
- Uncontrolled diabetes
- Known or detected positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B, or hepatitis C.
- Patients diagnosed with malignancy within the past two years. However, the following are excluded: non-melanoma skin cancer, melanoma in situ, localized prostate cancer (current PSA <0.1 ng/mL), treated thyroid cancer; or cervical carcinoma in situ or breast ductal/lobular carcinoma in situ within the past two years, provided there is currently no evidence of active disease.
Quoted from ClinicalTrials.gov, NCT07535762, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07535762, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.